Latest Breaking News On - Primary results from - Page 3 : comparemela.com

Study finds single dose of zilebesiran safely and effectively lowers blood pressure for six months

Study finds single dose of zilebesiran safely and effectively lowers blood pressure for six months
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPavel danilyukGeorgel bakrisAmerican heart associationUniversity of chicago medicineHypertension centerAmerican heart association scientific sessionsScientific sessionsComprehensive hypertension centerHigh blood pressureSustained blood pressure reduction withTherapeutic zilebesiranPrimary results fromPatients with

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.

Lazertinib versus osimertinibMutated advancedPrimary results fromNon small cell lung cancerAdvanced nsclcMetastatic nsclcMariposa trialMariposa studyEgfr mutatedEgfr mutantCombination therapyNovel therapyEgfr tkiTyrosine kinase inhibitorsMet inhibitorChrysalis study

Landmark Phase 3 MARIPOSA Study Shows

Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in.

South koreaUnited statesSoult ukpyolsiRegion flamandeRepublic of koreaJannsen cilag gmbJanssen cilag gmbByoung chul choEuropean society for medical oncologyAmerican lung associationEuropean unionJanssen research developmentYuhan corporationJanssen biotech incYonsei university college of medicineNational cancer institute

ACTRIMS 2023: MS fatigue eased with talk therapy, medication | Multiple Sclerosis News Today

Individual patients’ clinical situation, treatment goals should be considered when selecting interventions for MS-associated fatigue.

United statesSan diegoTiffany braleyForum on febAmericas committee for treatmentResearch in multiple sclerosisUniversity of michiganAmericas committeeMultiple sclerosisComparative effectiveness trialTelephone delivered cognitive behavioral therapyCombination therapyBoth interventionsPrimary results fromModified fatigue impact scalePatient global impression